- Home
- SWVL vs ARTV Comparison
SWVL vs ARTV Comparison
Compare SWVL & ARTV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SWVL
- ARTV
- Stock Information
- Founded
- SWVL 2017
- ARTV 2019
- Country
- SWVL United Arab Emirates
- ARTV United States
- Employees
- SWVL N/A
- ARTV N/A
- Industry
- SWVL Business Services
- ARTV
- Sector
- SWVL Consumer Discretionary
- ARTV
- Exchange
- SWVL Nasdaq
- ARTV NYSE
- Market Cap
- SWVL 44.5M
- ARTV 50.7M
- IPO Year
- SWVL N/A
- ARTV 2024
- Fundamental
- Price
- SWVL $4.15
- ARTV $1.53
- Analyst Decision
- SWVL
- ARTV Strong Buy
- Analyst Count
- SWVL 0
- ARTV 8
- Target Price
- SWVL N/A
- ARTV $18.14
- AVG Volume (30 Days)
- SWVL 6.1K
- ARTV 295.3K
- Earning Date
- SWVL 07-07-2025
- ARTV 05-08-2025
- Dividend Yield
- SWVL N/A
- ARTV N/A
- EPS Growth
- SWVL N/A
- ARTV N/A
- EPS
- SWVL N/A
- ARTV N/A
- Revenue
- SWVL $17,207,362.00
- ARTV N/A
- Revenue This Year
- SWVL N/A
- ARTV N/A
- Revenue Next Year
- SWVL N/A
- ARTV N/A
- P/E Ratio
- SWVL N/A
- ARTV N/A
- Revenue Growth
- SWVL N/A
- ARTV N/A
- 52 Week Low
- SWVL $2.40
- ARTV $1.47
- 52 Week High
- SWVL $8.05
- ARTV $17.31
- Technical
- Relative Strength Index (RSI)
- SWVL 45.93
- ARTV N/A
- Support Level
- SWVL $3.80
- ARTV N/A
- Resistance Level
- SWVL $4.48
- ARTV N/A
- Average True Range (ATR)
- SWVL 0.38
- ARTV 0.00
- MACD
- SWVL -0.05
- ARTV 0.00
- Stochastic Oscillator
- SWVL 42.17
- ARTV 0.00
About SWVL Swvl Holdings Corp
Swvl Holdings Corp is a technology-driven mobility company that aims to provide reliable, safe, cost-effective and environmentally responsible mass transit solutions. It provides mobility solutions for enterprises and government and individual commuters across-multiple markets with clients such as Amazon, Bosch, E&, P&G and Siemens. The Company operates in Egypt, Saudi Arabia and the UAE.
About ARTV ARTIVA BIOTHERAPEUTICS INC
Artiva Biotherapeutics Inc is a biopharmaceutical company. The company is engaged in advancing a pipeline of off-the-shelf, allogeneic NK cell therapies for the treatment of hematologic malignancies or solid tumors. The pipeline program of the company includes Artiva-Funded Trials and Collaborator-Funded Trials. The company pipeline includes AlloNK: is an allogeneic, off-the-shelf, cryopreserved NK cell therapy candidate designed to enhance the antibody-dependent cellular cytotoxicity (ADCC) effect of mAbs to drive B-cell. Others products includes: CAR-NK(AB201),CAR-NK(AB205).